Lyudmila Bazhenova Selected Research

Disease Progression

7/2023	ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.
9/2021	Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
2/2021	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study.
10/2019	Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
1/2019	Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.
12/2014	Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
2/2006	Intravascular lymphoma: a role for single-agent rituximab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lyudmila Bazhenova Research Topics

Disease

40	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2024 - 04/2010
31	Neoplasms (Cancer) 03/2024 - 01/2013
18	Lung Neoplasms (Lung Cancer) 01/2024 - 04/2011
7	Disease Progression 07/2023 - 02/2006
4	Neoplasm Metastasis (Metastasis) 01/2023 - 09/2014
4	Diarrhea 01/2023 - 10/2019
4	Circulating Neoplastic Cells 02/2015 - 02/2012
3	Vomiting 01/2023 - 02/2021
2	Malignant Mesothelioma 03/2024 - 12/2014
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2024 - 01/2018
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2024 - 02/2012
2	Exanthema (Rash) 07/2023 - 01/2018
2	Pulmonary Embolism 07/2023 - 12/2016
2	Nausea 01/2023 - 01/2023
2	Fatigue 01/2023 - 01/2018
2	Adenocarcinoma of Lung 03/2022 - 09/2017
2	Hypertension (High Blood Pressure) 01/2020 - 10/2019
1	Small Cell Carcinoma 04/2024
1	Inflammation (Inflammations) 01/2024
1	Long QT Syndrome 01/2024
1	Bradycardia 07/2023
1	Pericardial Effusion 07/2023
1	Pleural Effusion (Pleural Effusions) 07/2023
1	Colorectal Neoplasms (Colorectal Cancer) 10/2022
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/2022
1	Body Weight (Weight, Body) 01/2022
1	Hyperglycemia 02/2021
1	Hyponatremia 01/2020
1	Lymphopenia (Lymphocytopenia) 01/2020
1	Proteinuria 10/2019
1	Epilepsy (Aura) 01/2019
1	Pneumonia (Pneumonitis) 01/2019
1	Acne Vulgaris 01/2018
1	Carcinogenesis 01/2018

Drug/Important Bio-Agent (IBA)

10	ErbB Receptors (EGF Receptor)IBA 01/2023 - 03/2015
7	Tyrosine Kinase InhibitorsIBA 07/2023 - 12/2016
7	Phosphotransferases (Kinase)IBA 10/2022 - 04/2010
6	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2013
5	NivolumabIBA 01/2024 - 01/2021
5	PlatinumIBA 01/2023 - 02/2021
4	IpilimumabIBA 01/2024 - 09/2021
4	Proteins (Proteins, Gene)FDA Link 01/2024 - 07/2009
4	Alanine Transaminase (SGPT)IBA 01/2023 - 12/2016
4	Immune Checkpoint InhibitorsIBA 11/2022 - 11/2017
4	TropomyosinIBA 01/2022 - 01/2018
3	adagrasibIBA 01/2023 - 01/2022
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2023 - 01/2020
3	osimertinibIBA 01/2019 - 12/2016
2	alectinibIBA 07/2023 - 10/2021
2	CrizotinibIBA 07/2023 - 12/2010
2	trastuzumab deruxtecanIBA 05/2023 - 01/2022
2	mobocertinibIBA 01/2023 - 01/2021
2	entrectinibIBA 05/2022 - 01/2022
2	amivantamab-vmjwIBA 01/2022 - 01/2022
2	B7-H1 AntigenIBA 01/2022 - 01/2017
2	tyrosine receptor (receptor, tyrosine)IBA 01/2022 - 01/2021
2	Paclitaxel (Taxol)FDA LinkGeneric 02/2021 - 01/2021
2	Pemetrexed (MTA)FDA Link 02/2021 - 12/2014
2	selpercatinibIBA 01/2021 - 01/2020
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2019 - 01/2017
2	AntibodiesIBA 01/2018 - 08/2014
2	Circulating Tumor DNAIBA 10/2017 - 09/2017
2	Keratins (Keratin)IBA 01/2017 - 08/2014
1	repotrectinibIBA 01/2024
1	Anaplastic Lymphoma KinaseIBA 07/2023
1	TabletsIBA 01/2023
1	glycolic acid (glycolate)IBA 01/2023
1	EnzymesIBA 01/2023
1	ElectrolytesIBA 01/2023
1	AntiemeticsIBA 01/2023
1	SaltsIBA 01/2023
1	glesatinibIBA 01/2023
1	SuspensionsIBA 01/2023
1	Capsules (Microcapsules)IBA 01/2023
1	c-Mer Tyrosine KinaseIBA 10/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2022
1	sitravatinibIBA 10/2022
1	brigatinibIBA 09/2022
1	Axitinib (AG 013736)IBA 01/2022
1	palbociclibIBA 01/2022
1	avelumabIBA 01/2022
1	human ERBB2 proteinIBA 01/2022
1	pembrolizumabIBA 01/2022
1	rociletinibIBA 02/2021
1	Docetaxel (Taxotere)FDA Link 02/2021
1	Gemcitabine FDA Link 02/2021
1	DV281IBA 01/2021
1	veliparibIBA 01/2021
1	Carboplatin (JM8)FDA LinkGeneric 01/2021
1	Bevacizumab (Avastin)FDA Link 10/2019
1	agerafenibIBA 01/2019
1	eosinylphosphatidylethanolamine (EOPE)IBA 01/2019
1	Cetuximab (Erbitux)FDA Link 01/2018
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2018

Therapy/Procedure

23	Therapeutics 03/2024 - 02/2006
8	Drug Therapy (Chemotherapy) 01/2022 - 09/2014
7	Immunotherapy 01/2024 - 01/2017
5	Radiotherapy 01/2018 - 04/2011
1	Diet Therapy (Therapy, Diet) 01/2023
1	Chemoradiotherapy 01/2021